Rosacea
Conditions
Interventions
Treatment group:Dapsone tablets (100 mg/day).
Of these, 28 patients who agreed to participate in the collection of additional biospecimens constituted the biomarker exploration subgroup.
Sponsors
The Second Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 1. Patients of both sexes, aged 18-65 years, diagnosed with rosacea by professional dermatologists according to the Chinese Guidelines for the diagnosis and Treatment of rosacea (2021 edition); (2) Refractory criteria: insufficient response to at least two adequate and sufficient courses of conventional systemic therapy (such as doxycycline, minocycline, isotretinoin, etc.), and improvement of IGA score did not reach grade 1 after =8 weeks of treatment; 3. Sign the informed consent and be willing to cooperate with the use of the same topical preparation (ceramide moisturizer) during the study.
Exclusion criteria
Exclusion criteria: 1. Currently pregnant, breastfeeding or planning to become pregnant; 2. Glucose-6-phosphate dehydrogenase deficiency; 3. Allergy to dapsone or sulfonamides; 4. Patients with malignant tumors and other serious systemic diseases; 5. Patients with previous or ongoing systemic immunosuppressive therapy; 6. Patients with other facial diseases (seborrheic dermatitis, systemic lupus erythematosus, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Investigator’s global assessment (IGA);Clinician’s erythema assessment (CEA); | — |
Secondary
| Measure | Time frame |
|---|---|
| patient's self-assessment scale (PSA);Rosacea Quality of Life Index (RQoL);Skin moisture content;Transepidermal Water Loss (TEWL);Patient satisfaction;Image changes with octa-spectral facial imager;Proteomics; | — |
Countries
China
Contacts
Public ContactWu Jiawen
The Second Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed